"Targeting BCMA Achieves Deep and Durable Responses in Multiple Myeloma."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Targeting BCMA with the antibody-drug conjugate GSK2857916 is well tolerated in a phase I trial. Click to show full abstract

Targeting BCMA with the antibody-drug conjugate GSK2857916 is well tolerated in a phase I trial.

Keywords: targeting bcma; bcma achieves; responses multiple; durable responses; achieves deep; deep durable

Journal Title: Cancer discovery
Year Published: 2019

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended